Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
322 Leser
Artikel bewerten:
(1)

Osteotec and TriMed, Inc., agree distribution partnership for the Osteotec Silicone Finger Implant

NEWBURY, England, June 11, 2024 /PRNewswire/ -- Osteotec, a leading UK manufacturer and distributor of medical devices, is pleased to announce a strategic distribution partnership with TriMed, Inc., a medical device company based in Valencia, California, that develops solutions used in the treatment of orthopaedic injuries.

Osteotec Logo

This collaboration, launched in February, signifies a major advance in Osteotec's mission to extend the reach of its product portfolio across the United States, with a special focus on delivering its flagship product, the Osteotec Silicone Finger Implant.

A one-piece, ?exible silicone elastomer implant, the Osteotec Silicone Finger Implant is designed to improve the function of metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joints disabled by osteoarthritis, rheumatoid arthritis or joint trauma and reduce pain in affected joints.

Available in 11 sizes and supplied sterile, the Osteotec Silicone Finger Implant is placed in the proximal and distal intramedullary canals of either MCP or PIP joints during arthroplasty.

"TriMed is not only one of the leading innovators in the field of orthopaedics but shares our commitment to exceptional customer service and providing surgeons with options that improve patient outcomes," said Osteotec Sales and Marketing Director Dean Stockwell.

"Osteotec has successfully distributed the TriMed upper extremity portfolio in the UK for more than a decade, and we are proud to build on this long-term partnership to expand access to our products in the United States.

"We look forward to working with the TriMed team to grow and support sales of the Osteotec Silicone Finger Implant through our shared expertise, ensuring their customers receive the highest quality experience, service and support within the industry."

Designed and manufactured in the UK, the Osteotec Silicone Finger Implant and instrumentation has been in clinical use in the UK for more than 20 years and has been sold in more than a dozen markets across six continents since it was launched in 2004.

The strategic alliance between Osteotec and TriMed, Inc., is expected to make the Osteotec Silicone Finger Implant widely available across the United States for the first time, accelerating growth and contributing to significant sales and revenue increases.

Incorporated in 1997 to advance the treatment of complex periarticular fractures, TriMed's unique methods and inventive technologies have established the company as an industry leader in treating complex musculoskeletal pathologies of the upper and lower extremities.

"We're excited to be offering the Osteotec Silicone Finger Implant to our customers across the United States, and to be bringing another tried and tested product to the market that provides surgeons with more solutions," said TriMed Senior Vice President Jon Mills.

"We think that our team, customers and their patients will benefit from this successful collaboration, and it will also create even more opportunities for growth and ongoing success."

The Osteotec Silicone Finger Implant is available in the United States from TriMed now. For more information, visit trimedortho.com.

Editor's Notes

About Osteotec

Osteotec is a manufacturer and distributor of medical devices headquarter in Newbury, UK, with offices in Dublin and Malmö. Established in 1993, Osteotec has been supplying into the NHS and private healthcare sectors for the past 31 years.

Osteotec manufactures the Osteotec Silicone Finger, ChiroKlip and the Concentric Bone Graft System and is a distribution partner of choice for world-leading orthopaedic and spine partners including TriMed, SI-BONE, Enovis and Mathys.

Media Contact:

Ric Sumner
Head of Marketing
ric.sumner@orthocg.com | 020 3011 5574
For more information, visit - www.osteotec.com

About TriMed, Inc.

TriMed, Inc. offers solutions that treat a wide range of musculoskeletal pathologies of the extremities. A market leader that specializes in unique methods of fixation, in addition to its standard methods of fixation, TriMed, Inc. holds numerous patents within the field of orthopaedics. TriMed is headquartered in Valencia, CA with offices in Dublin.

Media Contact:

Jon Mills
Senior Vice President
jonmills@trimedortho.com | (661) 255-7406 x 140
For more information, visit - www.trimedortho.com

Logo - https://mma.prnewswire.com/media/2151731/4753255/Osteotec_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/osteotec-and-trimed-inc-agree-distribution-partnership-for-the-osteotec-silicone-finger-implant-302168391.html

© 2024 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.